Toronto, Ontario -- April 19, 2012 --
Theralase Technologies Inc. (TSX-V: TLT) announced today that it has been
issued a new U.S. Patent that expands the scope and capabilities of its
cancer-fighting proprietary Photo Dynamic Compound (PDC) technology. The patent provides Theralase with exclusive
rights to a new and advanced class of anti-cancer and anti-bacterial compounds until
2031.
Theralase
continues to expand its intellectual property holdings of cancer-fighting drug
compounds employed in conjunction with its proprietary therapeutic laser device
capabilities. The newly issued U.S. Patent expands the Company’s capability to
jointly employ its proprietary PDC and laser technologies in the destruction of
a diverse variety of common cancers, bacteria and viruses. The new PDC patent
identifies a special class of proprietary Photo Dynamic Compounds that can be
employed in the destruction of bulk tumours.
Theralase
recently reported that the growth of subcutaneous (under the skin) colon cancer
tumours in mouse subjects, which were simultaneously treated with the Theralase
anti-cancer PDC technologies have continued to thrive cancer-free for more than
55 days post-treatment and without any side effects.
Based on the
Company’s recent successes in the research and development of its portfolio of
patented PDCs, there is increased confidence that applications can be made to
the regulatory bodies for human trials in the relatively near future.
About Theralase
Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs,
develops, manufactures and markets patented, superpulsed laser technology
utilized in biostimulation and biodestruction applications. Theralase
technology is safe and effective in treating pain, inflammation and for tissue
regeneration of neural muscular skeletal conditions and wound healing.
Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that
are able to target and destroy cancers, bacteria and viruses when light
activated by Theralase’s proprietary and patented laser technology.
For further information please visit www.theralase.com,
regulatory filings may be viewed by visiting www.sedar.com.
This press release contains
forward-looking statements which reflect the Company's current expectations
regarding future events. The forward-looking statements involve risks and
uncertainties. Actual results could differ materially from those projected
herein. The Company disclaims any obligation to update these forward-looking
statements.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the policies of the
TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of
this release.
For More Information:
Roger Dumoulin-White
President & Chief Executive Officer
416-447-8455 ext. 225
rwhite@theralase.com
Kristina Hachey
Chief Financial Officer
416-447-8455 ext. 224
khachey@theralase.com
Arkady Mandel
Chief Scientific Officer
416-447-8455 ext. 242
Greg Bewsh
Director of Investor Relations
416-447-8455 ext. 262
gbewsh@theralase.com
No comments:
Post a Comment